PUMA BIOTECHNOLOGY, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $31.1M | $30.3M | $21.6M | $2.0K | $-29.1M | $-60.0M | $-75.6M | $-113.6M |
| Depreciation & Amortization | $10.9M | $11.5M | $11.5M | $9.8M | $11.3M | $10.0M | $8.1M | $7.4M |
| Depreciation | $400.0K | $400.0K | $400.0K | $600.0K | $700.0K | $900.0K | $900.0K | $1.1M |
| Amortization | $9.7M | $9.7M | $8.0M | $8.0M | $8.0M | $6.3M | $3.9M | $3.9M |
| Stock-Based Compensation | $6.9M | $8.2M | $10.2M | $11.8M | $32.6M | $36.6M | $57.3M | $86.9M |
| Net Cash from Operating Activities | $41.8M | $38.9M | $27.0M | $-15.8M | $20.7M | $773.0K | $22.4M | $-24.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $71.0K | $56.0K | $140.0K | $0 | $0 | $46.0K | $306.0K | $439.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-36.2M | $-20.4M | $-19.1M | $7.1M | $-10.9M | $33.4M | $5.2M | $-57.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-45.2M | $-33.8M | $0 | $12.2M | $-31.9M | $-9.9M | $-67.1M | $108.5M |
| Net Change in Cash | $-39.6M | $-15.4M | $7.9M | $3.5M | $-22.2M | $24.2M | $-39.5M | $26.7M |
| Free Cash Flow | $41.7M | $38.9M | $26.9M | $-15.8M | $20.7M | $727.0K | $22.1M | $-24.5M |
Plant trees that other men will sit under.